Thermo Fisher Scientific BCL9L Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

0.04-0.4 µg/mL

View 1 publication 1 publication

Immunohistochemistry (Paraffin) (IHC (P))

1:50-1:200

-

Immunocytochemistry (ICC/IF)

0.25-2 µg/mL

-

Product Specifications

Species Reactivity

Human

Published species

Human

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Recombinant protein corresponding to Human BCL9L. Recombinant protein control fragment (Product #RP-100464). if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:BCL9L,uniProtId:Q86UU0-1,ncbiNodeId:9606,antigenRange:1389-1491,antigenLength:1499,antigenImageFileName:PA5-61946_BCL9L_Q86UU0-1_Rabbit.svg,antigenImageFileNamePDP:PA5-61946_BCL9L_Q86UU0-1_Rabbit_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.1 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS, pH 7.2, with 40% glycerol

Contains

0.02% sodium azide

Storage conditions

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Shipping conditions

Wet ice

RRID

AB_2638513

Product Specific Information

Immunogen sequence: MSMCHPGQMS LLGRTGVPPQ QGMVPHGLHQ GVMSPPQGLM TQQNFMLMKQ RGVGGEVYSQ PPHMLSPQGS LMGPPPQQNL MVSHPLRQRS VSLDSQMGYL PAP

Highest antigen sequence identity to the following orthologs: Mouse - 98%, Rat - 97%.

Target Information

Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.